The circadian gene CRY2 is associated with breast cancer aggressiveness possibly via epigenomic modifications

Tumor Biology

Volumn 36, Issue 5, 2015, Pages 3533-3539

  Mao, Yingying ^a,b,d   Fu, Alan ^a   Hoffman, Aaron E ^c   Jacobs, Daniel I ^a   Jin, Mingjuan ^b   Chen, Kun ^b   Zhu, Yong ^a,d  

^a YALE UNIVERSITY   (United States)

^b ZHEJIANG UNIVERSITY   (China)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

Author keywords

Biomarker; Breast cancer; CRY2; DNA methylation; Network analysis

Indexed keywords

BIOLOGICAL MARKER; CRYPTOCHROME 2; TUMOR MARKER; CRY2 PROTEIN, HUMAN; CRYPTOCHROME;

ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CIRCADIAN RHYTHM; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA ISOLATION; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; IN VITRO STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RNA ISOLATION; BIOSYNTHESIS; BREAST TUMOR; CANCER STAGING; CARCINOGENESIS; CPG ISLAND; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC EPIGENESIS; GENETICS; HUMAN GENOME; MCF 7 CELL LINE; PATHOLOGY;

BREAST NEOPLASMS; CARCINOGENESIS; CPG ISLANDS; CRYPTOCHROMES; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENE SILENCING; GENOME, HUMAN; HUMANS; MCF-7 CELLS; NEOPLASM STAGING;

EID: 84929955999     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-014-2989-3     Document Type: Article

References (32)

1. Kondratov RV, Gorbacheva VY, Antoch MP. The role of mammalian circadian proteins in normal physiology and genotoxic stress responses. Curr Top Dev Biol. 2007;78:173–216.
2. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002;418:935–41.
3. Duffield GE, Best JD, Meurers BH, Bittner A, Loros JJ, Dunlap JC. Circadian programs of transcriptional activation, signaling, and protein turnover revealed by microarray analysis of mammalian cells. Curr Biol. 2002;12:551–7.
4. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003;3:350–61.
5. Thresher RJ, Vitaterna MH, Miyamoto Y, Kazantsev A, Hsu DS, Petit C, et al. Role of mouse cryptochrome blue-light photoreceptor in circadian photoresponses. Science. 1998;282:1490–4.
6. van der Spek PJ, Kobayashi K, Bootsma D, Takao M, Eker AP, Yasui A. Cloning, tissue expression, and mapping of a human photolyase homolog with similarity to plant blue-light receptors. Genomics. 1996;37:177–82.
7. Unsal-Kacmaz K, Mullen TE, Kaufmann WK, Sancar A. Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol. 2005;25:3109–16.
8. Gauger MA, Sancar A. Cryptochrome, circadian cycle, cell cycle checkpoints, and cancer. Cancer Res. 2005;65:6828–34.
9. Zhu Y, Stevens RG, Hoffman AE, Fitzgerald LM, Kwon EM, Ostrander EA, et al. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res. 2009;69:9315–22.
10. Hoffman AE, Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, et al. Clock-cancer connection in non-Hodgkin’s lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2. Cancer Res. 2009;69:3605–13.
11. Hoffman AE, Zheng T, Yi CH, Stevens RG, Ba Y, Zhang Y, et al. The core circadian gene cryptochrome 2 influences breast cancer risk, possibly by mediating hormone signaling. Cancer Prevent Res (Philadelphia, Pa). 2010;3:539–48.
12. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia. 2007;9:166–80.
13. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, Ehrmann J, et al. Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer. 2007;7:55.
14. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449:557–63.
15. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, et al. X chromosomal abnormalities in basal-like human breast cancer. Cancer Cell. 2006;9:121–32.
16. Gluck S, Ross JS, Royce M, McKenna Jr EF, Perou CM, Avisar E, et al. Tp53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine +/− trastuzumab. Breast Cancer Res Treat. 2012;132:781–91.
17. Ma XJ, Dahiya S, Richardson E, Erlander M, Sgroi DC. Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Res. 2009;11:R7.
18. Radvanyi L, Singh-Sandhu D, Gallichan S, Lovitt C, Pedyczak A, Mallo G, et al. The gene associated with trichorhinophalangeal syndrome in humans is overexpressed in breast cancer. Proc Natl Acad Sci U S A. 2005;102:11005–10.
19. Zhao H, Langerod A, Ji Y, Nowels KW, Nesland JM, Tibshirani R, et al. Different gene expression patterns in invasive lobular and ductal carcinomas of the breast. Mol Biol Cell. 2004;15:2523–36.
20. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, Zhao H, et al. Stromal gene expression predicts clinical outcome in breast cancer. Nat Med. 2008;14:518–27.
21. McCain J. The cancer genome atlas: new weapon in old war? Biotechnol Healthc. 2006;3:46–51B.
22. Ringner M, Fredlund E, Hakkinen J, Borg A, Staaf J. GOBO: Gene Expression-Based Outcome for Breast Cancer Online. PLoS One. 2011;6:e17911.
23. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, Cho RJ, et al. A network-based analysis of systemic inflammation in humans. Nature. 2005;437:1032–7.
24. Hoffman AE, Zheng T, Ba Y, Stevens RG, Yi CH, Leaderer D, et al. Phenotypic effects of the circadian gene cryptochrome 2 on cancer-related pathways. BMC Cancer. 2010;10:110.
25. Xiang S, Coffelt SB, Mao L, Yuan L, Cheng Q, Hill SM. Period-2: A tumor suppressor gene in breast cancer. J Circadian Rhythms. 2008;6:4.
26. Bourguignon LY, Singleton PA, Zhu H, Diedrich F. Hyaluronan-mediated cd44 interaction with rhogef and rho kinase promotes grb2-associated binder-1 phosphorylation and phosphatidylinositol 3-kinase signaling leading to cytokine (macrophage-colony stimulating factor) production and breast tumor progression. J Biol Chem. 2003;278:29420–34.
27. Orian-Rousseau V, Morrison H, Matzke A, Kastilan T, Pace G, Herrlich P, et al. Hepatocyte growth factor-induced ras activation requires erm proteins linked to both cd44v6 and f-actin. Mol Biol Cell. 2007;18:76–83.
28. Bourguignon LY, Wong G, Earle C, Krueger K, Spevak CC. Hyaluronan-cd44 interaction promotes c-src-mediated twist signaling, microrna-10b expression, and rhoa/rhoc up-regulation, leading to rho-kinase-associated cytoskeleton activation and breast tumor cell invasion. J Biol Chem. 2010;285:36721–35.
29. Kai K, Arima Y, Kamiya T, Saya H. Breast cancer stem cells. Breast Cancer. 2010;17:80–5.
30. Marhaba R, Zoller M. Cd44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol. 2004;35:211–31.
31. Louderbough JM, Schroeder JA. Understanding the dual nature of cd44 in breast cancer progression. Mol Cancer Res. 2011;9:1573–86.
32. Vaillant F, Merino D, Lee L, Breslin K, Pal B, Ritchie ME, et al. Targeting bcl-2 with the bh3 mimetic abt-199 in estrogen receptor-positive breast cancer. Cancer Cell. 2013;24:120–9.